Vaccine Development

Vaccine Development Regulatory Affairs Vaccines Vaccines Vaccine Development Vaccine Development Vulnerable Populations Vaccination Infectious Diseases Public Health

3 ARTICLES

last mo.

FDA approves Moderna’s mNEXSPIKE vaccine for seniors and high-risk Americans

Phase 3 data showed the new booster provided stronger protection than Moderna’s original shot, with distribution set for the 2025–2026 respiratory season.

16 ARTICLES

last mo.

FDA Grants Limited Approval to Novavax’s COVID-19 Vaccine